ReSPECT-LM Data from SNO/ASCO

by | Aug 12, 2024 | LM

Highlights include: > Respect-LM dosing shows continued feasibility and safety of up to 44 mCi of intrathecal Rhenium (186Re) Obisbemeda > High absorbed radiation doses, mean circulating tumor cell reductions, and median overall survival of 12 months continue to...

SNO/ASCO Bronze Supporter

by | Aug 2, 2024 | Uncategorized

Plus Therapeutics is proud to be a Bronze Supporter and Exhibitor at the SNO / ASCO CNS Conference this year! Come by our booth, posters, and presentations we have going on throughout the conference. Detail including times and presentation titles:...

SNO/ASCO Symposium

by | Aug 1, 2024 | Uncategorized

You’re Invited to our symposium “Emerging Novel Diagnostic and Therapeutic Approaches for Leptomeningeal Metastases,” presented at the SNO/ASCO CNS conference in Denver. More information & RSVP: https://bit.ly/4bM777e “Emerging Novel...

2024 SNO/ASCO Curtain Raiser

by | Jul 25, 2024 | Uncategorized

UPCOMING PRESENTATIONS: Plus Therapeutics Showcases Leptomeningeal Metastases Programs at 2024 SNO/ASCO Conference and scheduled to present new data, highlighting progress in its therapeutics and diagnostics programs for Leptomeningeal Metastases Read the full details...